

# West Virginia Medicaid Drug Utilization Review Board Minutes

February 27, 2019

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

## **Members:**

Lester Labus, MD, Chair  
K.C. Lovin, PA-C, Vice Chair  
Ernest Miller, DO  
Kate Forman, PharmD  
Michael Ballow, PharmD  
Michael Lonsinger, PharmD  
C.K. Babcock, PharmD  
John Vanin, MD  
Myra Chiang, MD  
Chris Terpening, PharmD, PhD  
Mary Nemeth-Pyles, MSN, RN, CS  
Scott Brown, RPh (via phone)

## **Members Absent:**

Christopher Booth, PharmD

## **DHHR/BMS Staff:**

Vicki Cunningham, RPh, Director of Pharmacy Services  
Brian Thompson, MS, PharmD, DUR Coordinator  
Lori Moles, RPh, Staff Pharmacist  
Gail Goodnight, RPh, Rebate Manager  
Bill Hopkins, Pharmacy Operations Manager  
Doug Sorvig, Administrative Assistant

## **Contract Staff:**

Steve Small, MS, RPh, Rational Drug Therapy Program (RDTP)  
Angela Wowczuk, PharmD, Rational Drug Therapy Program (RDTP)  
Alesha Heil, PharmD, SEMP  
Rob Stanton, PharmD, Marshall University  
Kim Broedel-Zaugg, RPh, Marshall University  
John Willis, Marshall University  
Eric Sears, RPh, Molina Medicaid Solutions  
Brent Breeding, RPh, Change Healthcare  
Laureen Biczak, MD, Change Healthcare (via phone)

## **I. INTRODUCTIONS**

- A. Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting at 4:08 p.m. EDT. The DUR Board and attendees introduced themselves.

## **II. APPROVAL OF MINUTES FROM September 26, 2018 DUR BOARD MEETING**

- A. A motion was made, seconded, and approved to accept the minutes from the previous DUR Board meeting.

## **III. OLD BUSINESS**

- 1. None

## **IV. NEW BUSINESS**

- A. **Speakers** – No Speakers at Meeting
- B. **Updates from the January 23, 2019 Pharmacy & Therapeutics Committee Meeting** – The board was advised that the P&T Committee meeting was cancelled due to lack of a quorum.
- C. **PDL Prior Authorization Criteria (Attachment A)**
  - 1. **Cytokine and CAM antagonists** – Approved as presented
  - 2. **Ophthalmics, Glaucoma agents (prostaglandin analogs) – Vyzulta** – Approved as presented
  - 3. **Pituitary Suppressive Agents, LHRH (new PDL class)** – Approved as presented
  - 4. **CGRP Antagonists** – Approved as presented.
  - 5. **Xolair** – Approved with changes (60 days of H1 antihistamine dose at 2x-4x the usual dose and at least 30 days of combination therapy)

## **V. REPORTS**

- A. **Molina Quarterly Report** – Eric Sears presented an overview of the Molina 2018 Fourth Quarter Report (Attachment B). The presentation included a review of the DUR Quarterly Overall Summary Report.
- B. **Rational Drug Therapy Program** – Angela Wowczuk presented a review of the prior authorization program for the Fourth Quarter 2018. (Attachment C). Steve Small announced his retirement. We thank him for his many years of distinguished service.
- C. **SEMP (Safe Effective Management of Pain)** – Alesha Heil presented an overview of the SEMP program (Attachment D).
- D. **Marshall University, Retro DUR Program** – Rob Stanton introduced himself and his team to the Board the new Retro DUR program vendor.
- E. **OTHER BUSINESS – OPEN TO THE FLOOR**
  - A. Steve Small, RDTP, announced that he was retiring and that this would be his last DUR board meeting. The Board thanked him for his partnership with the WV Medicaid Program and his service to the people of West Virginia.

## **VI. NEXT MEETING AND ADJOURNMENT**

- A. A motion to adjourn the meeting was made, seconded, and passed.
- B. The meeting concluded at 5:06 p.m. EDT.
- C. The next meeting will be Wednesday, May 22, 2019 from 4:00 p.m.–6:00 p.m. and located at WVDHHR.